2024
Smartband-based smoking detection and real-time brief mindfulness intervention: findings from a feasibility clinical trial
Horvath M, Pittman B, O’Malley S, Grutman A, Khan N, Gueorguieva R, Brewer J, Garrison K. Smartband-based smoking detection and real-time brief mindfulness intervention: findings from a feasibility clinical trial. Annals Of Medicine 2024, 56: 2352803. PMID: 38823419, PMCID: PMC11146247, DOI: 10.1080/07853890.2024.2352803.Peer-Reviewed Original ResearchConceptsBrief mindfulness interventionsMindfulness exercisesTreatment startersMindfulness interventionSmoking interventionsOnline mindfulness trainingWhite non-HispanicMindfulness trainingTreatment fidelityFeasibility measuresHelpfulness ratingsNon-HispanicDaily smokersPredicting smokingReduce smokingExerciseSmokingCigarette smokingInterventionLow completenessAdherenceParticipantsSmartbandAcceptanceMindfulnessA randomized controlled trial of potential tobacco policies prohibiting menthol flavor in cigarettes and e-cigarettes: a study protocol
Bold K, Sharma A, Haeny A, Gueorguieva R, Buta E, Baldassarri S, Lempert L, Krishnan-Sarin S, O’Malley S. A randomized controlled trial of potential tobacco policies prohibiting menthol flavor in cigarettes and e-cigarettes: a study protocol. BMC Psychiatry 2024, 24: 201. PMID: 38475757, PMCID: PMC10935798, DOI: 10.1186/s12888-024-05619-0.Peer-Reviewed Original ResearchConceptsSmoking menthol cigarettesE-cigarettesCigarette useReduce tobacco-related health disparitiesTobacco-related health disparitiesMenthol cigarettesRates of menthol cigarette useTobacco use statusMenthol cigarette useRandomized controlled trialsPublic health problemHealth disparitiesTobacco policiesFlavored e-cigarettesSmoke-freeMenthol flavorsMenthol policiesBlack adultsQuit smokingNon-Black participantsSmoking behaviorFollow-up visitHealth problemsSecondary outcomesE-cigarette productsIllusory generalizability of clinical prediction models
Chekroud A, Hawrilenko M, Loho H, Bondar J, Gueorguieva R, Hasan A, Kambeitz J, Corlett P, Koutsouleris N, Krumholz H, Krystal J, Paulus M. Illusory generalizability of clinical prediction models. Science 2024, 383: 164-167. PMID: 38207039, DOI: 10.1126/science.adg8538.Peer-Reviewed Original Research
2023
Developing Researchers with Expertise in Sex as a Biological Variable through SCORE Career Enhancement Core Center Programs
Zakiniaeiz Y, Peltier M, Mineur Y, Gueorguieva R, Picciotto M, Petrakis I, Cosgrove K, McKee S. Developing Researchers with Expertise in Sex as a Biological Variable through SCORE Career Enhancement Core Center Programs. Journal Of Women's Health 2023, 32: 852-857. PMID: 37585509, PMCID: PMC10457604, DOI: 10.1089/jwh.2023.0015.Peer-Reviewed Original ResearchNaltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial
Grilo C, Lydecker J, Gueorguieva R. Naltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial. Psychological Medicine 2023, 53: 7775-7784. PMID: 37366017, PMCID: PMC10751383, DOI: 10.1017/s0033291723001800.Peer-Reviewed Original ResearchConceptsNaltrexone/bupropionBinge-eating disorderBinge-eating remissionAcute treatmentMaintenance treatmentBinge-eating frequencyDouble-blind placebo-controlled trialBehavioral weight loss therapyWeight lossCo-occurring obesitySuccessful acute treatmentPlacebo-controlled trialWeight loss therapySignificant additional weight lossSingle-site trialAdditional weight lossAcute efficacyRemission rateAdult patientsComorbid obesityBupropionInitial interventionPosttreatment assessmentRespondersPlaceboGambling participation among Connecticut adolescents from 2007 to 2019: Potential risk and protective factors
Stefanovics E, Gueorguieva R, Zhai Z, Potenza M. Gambling participation among Connecticut adolescents from 2007 to 2019: Potential risk and protective factors. Journal Of Behavioral Addictions 2023, 12: 490-499. PMID: 37335777, PMCID: PMC10316163, DOI: 10.1556/2006.2023.00027.Peer-Reviewed Original ResearchConceptsPrevalence of gamblingGambling participationPatterns of gamblingSocial supportSocial support programsGambling advertisementsTraumatic experiencesMedia coverageState of ConnecticutSocio-demographic characteristicsAffective concernsSubstance useConnecticut high school studentsGamblingAdolescent gamblingAnonymous self-completed questionnairePotential risk factorsParticipationSupport programsPublic health concernSelf-completed questionnaireCurrent substance useSocio-demographic dataCross-sectional surveyWarrants further studyDoes Symptom-Onset Treatment With Sertraline Improve Functional Impairment for Individuals With Premenstrual Dysphoric Disorder?
Yonkers K, Altemus M, Gilstad-Hayden K, Kornstein S, Gueorguieva R. Does Symptom-Onset Treatment With Sertraline Improve Functional Impairment for Individuals With Premenstrual Dysphoric Disorder? Journal Of Clinical Psychopharmacology 2023, 43: 320-325. PMID: 37212651, PMCID: PMC10313784, DOI: 10.1097/jcp.0000000000001700.Peer-Reviewed Original ResearchConceptsPremenstrual dysphoric disorderFunctional impairmentSymptom onsetPMDD symptomsDysphoric disorderAnger/irritabilityDaily treatmentActive treatmentFunctional outcomeClinical trialsFunctional improvementSecondary analysisCausal mediation analysisSertralineSeverity of problemsImpairmentNonsignificant direct effectDaily ratingsPlaceboTreatmentFace validitySymptomsIrritabilityDisordersSignificant indirect effectCognitive‐behavioral therapy for binge‐eating disorder for non‐responders to initial acute treatments: Randomized controlled trial
Grilo C, Lydecker J, Gueorguieva R. Cognitive‐behavioral therapy for binge‐eating disorder for non‐responders to initial acute treatments: Randomized controlled trial. International Journal Of Eating Disorders 2023, 56: 1544-1553. PMID: 37144325, PMCID: PMC10524840, DOI: 10.1002/eat.23975.Peer-Reviewed Original ResearchConceptsInitial acute treatmentBinge-eating disorderCognitive behavioral therapyAcute treatmentBinge-eating frequencyInitial interventionTherapist-led cognitive behavioural therapyInitial pharmacological treatmentTreat remission ratesEvidence-based treatmentsSingle-site trialAcute efficacyRemission rateAdult patientsInitial treatmentPharmacological treatmentPatientsPosttreatment assessmentBehavioral treatmentSufficient benefitTherapyDisordersInterventionTreatmentPharmacotherapyRandomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia
Surti T, Ranganathan M, Johannesen J, Gueorguieva R, Deaso E, Kenney J, Krystal J, D'Souza D. Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia. Schizophrenia Research 2023, 256: 36-43. PMID: 37141764, PMCID: PMC10257994, DOI: 10.1016/j.schres.2023.04.010.Peer-Reviewed Original ResearchConceptsGlycine transporter 1Cytochrome P450 2D6 extensive metabolizersGlyT1 inhibitorsWeeks of washoutWeeks of CTMedication adherenceReceptor hypofunctionImpaired neuroplasticityPharmacodynamic variabilityNMDAR functionExtensive metabolizersTreatment periodPsychotic symptomsStable outpatientsCognitive impairmentGlyT1 occupancyTransporter 1CTNeuroplasticityCognitive training strategiesSchizophreniaComputerized CTCognitive performanceAugmentation studiesGreater improvementA Network Analysis of Cigarette Craving.
Aslan M, Sala M, Gueorguieva R, Garrison K. A Network Analysis of Cigarette Craving. Nicotine & Tobacco Research 2023, 25: 1155-1163. PMID: 36757093, PMCID: PMC10202645, DOI: 10.1093/ntr/ntad021.Peer-Reviewed Original ResearchThe first nicotine product tried is associated with current multiple nicotine product use and nicotine dependence among a nationally representative sample of U.S. youths
Simon P, Buta E, Jackson A, Camenga D, Kong G, Morean M, Bold K, Davis D, Krishnan-Sarin S, Gueorguieva R. The first nicotine product tried is associated with current multiple nicotine product use and nicotine dependence among a nationally representative sample of U.S. youths. Preventive Medicine 2023, 169: 107437. PMID: 36731754, PMCID: PMC10507373, DOI: 10.1016/j.ypmed.2023.107437.Peer-Reviewed Original ResearchConceptsNicotine product useSymptoms of dependenceNicotine dependenceMultiple product useSmokeless tobaccoNicotine productsProduct useSeparate multinomial logistic regression modelsHealth Study Waves 1Wave 1Smokeless tobacco usersHigher nicotine dependence scoresNicotine dependence scoresDemographic factorsLogistic regression modelsMultinomial logistic regression modelsMultivariable modelTobacco usersHigh riskDependence scoresSymptomsGreater likelihoodUse statusWave 4Regression modelsExamining racial differences in smoking outcomes among smokers enrolled in an intravenous nicotine infusion study
Schwartz E, Palmisano A, Gueorguieva R, DeVito E, Sofuoglu M. Examining racial differences in smoking outcomes among smokers enrolled in an intravenous nicotine infusion study. Addictive Behaviors 2023, 140: 107615. PMID: 36640662, PMCID: PMC9911383, DOI: 10.1016/j.addbeh.2023.107615.Peer-Reviewed Original ResearchConceptsSmoking-related illnessesNegative drug effectsNicotine clearanceOvernight abstinenceNicotine infusionDrug effectsMentholated cigarettesWhite individualsBlack individualsAcute pharmacologic effectsSmoking-related morbiditySmoking-related diseasesAdministration of nicotineSmoking-related outcomesSubjective drug effectsShort-term abstinenceLower ratesTrend level differenceLarge racial disparitiesNicotine administrationNicotine dosesTrend-level significancePharmacologic effectsTreatment strategiesOutcome measures
2022
Models for Zero-Inflated and Overdispersed Correlated Count Data: An Application to Cigarette Use
Pittman B, Buta E, Garrison K, Gueorguieva R. Models for Zero-Inflated and Overdispersed Correlated Count Data: An Application to Cigarette Use. Nicotine & Tobacco Research 2022, 25: 996-1003. PMID: 36318799, PMCID: PMC10077942, DOI: 10.1093/ntr/ntac253.Peer-Reviewed Original ResearchConceptsCorrelated count dataCount outcomesCount dataSubject-specific interpretationZero-InflatedIncorrect statistical inferenceStatistical inferenceCorrelated countsPoisson distributionOverdispersionModel assumptionsPoisson modelRandom effectsHurdle Poisson modelProper modelNegative binomial modelBinomial modelSuch dataAppropriate modelBest fitLarge varianceTobacco researchSuch outcomesModel fitTraining app
2020
Two‐part models for repeatedly measured ordinal data with “don't know” category
Gueorguieva R, Buta E, Morean M, Krishnan‐Sarin S. Two‐part models for repeatedly measured ordinal data with “don't know” category. Statistics In Medicine 2020, 39: 4574-4592. PMID: 32909252, PMCID: PMC8025667, DOI: 10.1002/sim.8739.Peer-Reviewed Original ResearchConceptsAdaptive Gaussian quadratureCorrelated random effectsSAS PROC NLMIXEDOrdinal dataMaximum likelihood estimationTerms of biasStatistical dependenceNominal modelGaussian quadraturePROC NLMIXEDLikelihood estimationPartial orderingEstimation algorithmTwo-part modelModel formulationSimulation studyRandom effectsPredictor effectsSubmodelsOrdinal natureFormulationNLMIXEDQuadratureModelOrderingData Visualization Tools of Tobacco Product Use Patterns, Transitions and Sex Differences in the PATH Youth Data
Gueorguieva R, Buta E, Simon P, Krishnan-Sarin S, O’Malley S. Data Visualization Tools of Tobacco Product Use Patterns, Transitions and Sex Differences in the PATH Youth Data. Nicotine & Tobacco Research 2020, 22: 1901-1908. PMID: 32219313, PMCID: PMC7542650, DOI: 10.1093/ntr/ntaa056.Peer-Reviewed Original ResearchConceptsTobacco product use patternsMultiple tobacco product useProduct use patternsTobacco product useE-cigarettesProduct useTobacco productsHookah useWave 1Wave 2Common tobacco productsTobacco use patternsE-cigarette useSex differencesInitiation of usePatterns of useHealth StudyAdolescent girlsYear old youthRelative frequencyUnweighted frequenciesCigarettesOlder youthUse patternsPopulation Assessment
2019
Influence of combined treatment with naltrexone and memantine on alcohol drinking behaviors: a phase II randomized crossover trial
Krishnan-Sarin S, O’Malley S, Franco N, Cavallo DA, Tetrault JM, Shi J, Gueorguieva R, Pittman B, Krystal JH. Influence of combined treatment with naltrexone and memantine on alcohol drinking behaviors: a phase II randomized crossover trial. Neuropsychopharmacology 2019, 45: 319-326. PMID: 31590179, PMCID: PMC6901445, DOI: 10.1038/s41386-019-0536-z.Peer-Reviewed Original ResearchConceptsAlcohol drinking behaviorFirst treatment periodTreatment periodNumber of drinksCrossover trialDrinking behaviorEfficacy of naltrexoneOpioid antagonist naltrexoneNMDA antagonist memantinePositive family historyDay treatment periodSelf-administration periodAlcohol-induced stimulationAd lib accessMemantine treatmentAntagonist naltrexoneOpioid systemFamily historyNTXPriming drinkMemantineNaltrexoneAlcohol cravingHeavy drinkersAlcohol dependence
2018
Association between physical exercise and mental health in 1·2 million individuals in the USA between 2011 and 2015: a cross-sectional study
Chekroud SR, Gueorguieva R, Zheutlin AB, Paulus M, Krumholz HM, Krystal JH, Chekroud AM. Association between physical exercise and mental health in 1·2 million individuals in the USA between 2011 and 2015: a cross-sectional study. The Lancet Psychiatry 2018, 5: 739-746. PMID: 30099000, DOI: 10.1016/s2215-0366(18)30227-x.Peer-Reviewed Original ResearchConceptsMental health burdenCross-sectional studyHealth burdenExercise typeMental healthPhysical exerciseBehavioral Risk Factor Surveillance System surveyPast monthBody mass index categoriesEffective clinical targetsPrevention's Behavioral Risk Factor Surveillance System (BRFSS) surveysSelf-reported mental healthFrequency of exerciseSelf-reported physical healthFunction of exerciseMultiple sensitivity analysesPoor mental healthTerms of ageCause mortalityPrevious diagnosisPotential confoundersInterventional studyCardiovascular diseaseReduced riskIndex categories
2017
Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis
Gueorguieva R, Chekroud AM, Krystal JH. Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis. The Lancet Psychiatry 2017, 4: 230-237. PMID: 28189575, PMCID: PMC5340978, DOI: 10.1016/s2215-0366(17)30038-x.Peer-Reviewed Original ResearchConceptsActive medicationActive treatmentClinical trialsDepression severityHamilton Depression Rating Scale scoresDepression Rating Scale scoresClinical Global Impression scoresIndividual patient-level dataDouble-blind treatmentPlacebo-controlled trialPatterns of relapseGlobal Impression scoresIndividual patient dataPrevention of relapseTrajectory class membershipTreatment of depressionMajor depressive disorderRating Scale scoresPatient-level dataPost-traumatic stress disorderTreatment discontinuationAntidepressant treatmentClinical responseAlcohol Research CenterAntidepressant medication
2016
Correlated probit analysis of repeatedly measured ordinal and continuous outcomes with application to the Health and Retirement Study
Grigorova D, Gueorguieva R. Correlated probit analysis of repeatedly measured ordinal and continuous outcomes with application to the Health and Retirement Study. Statistics In Medicine 2016, 35: 4202-4225. PMID: 27222058, DOI: 10.1002/sim.6982.Peer-Reviewed Original Research
2015
An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate
Gueorguieva R, Wu R, Tsai WM, O’Connor P, Fucito L, Zhang H, O’Malley S. An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate. European Neuropsychopharmacology 2015, 25: 1586-1599. PMID: 26141511, PMCID: PMC4600651, DOI: 10.1016/j.euroneuro.2015.06.006.Peer-Reviewed Original ResearchConceptsAcamprosate effectHeavy drinkingShort abstinenceEnhanced treatment responseMonths of treatmentSubgroup of patientsBody mass indexDrug plasma levelsIdentification of subgroupsBetter prognosisLower BMIMass indexPlasma levelsGlutamatergic hyperactivityTreatment responseAcamprosateCOMBINE StudyPrior treatmentLarger studyConsecutive daysAbstinencePretreatment abstinenceTreatment effectsCognitive inefficiencySubgroups